Potassium phosphate


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Hypophosphataemia Up to 100 mmol/day of phosphate. Adjunct to urinary antibacterials; Prophylaxis of Ca renal calculi 7.4 mmol of phosphate 4 times/day. IV Severe hypophosphataemia As monobasic potassium phosphate: Up to 10 mmol phosphate over 12 hours and repeated every 12 hours until serum phosphate exceeds 0.3 mmol/L.
Dosage Details
Intravenous
Severe hypophosphataemia
Adult: As monobasic potassium phosphate: Up to 10 mmol phosphate over 12 hours and repeated every 12 hours until serum phosphate exceeds 0.3 mmol/L.
Child: 0.15-0.33 mmol/kg administered over 6 hours. The dose may be repeated at 6 hour-intervals until serum phosphate exceeds 0.6 mmol/L. Rate of infusion should not exceed 0.2 mmol/kg/hour.

Oral
Adjunct to urinary antibacterials, Prophylaxis of calcium renal calculi
Adult: 7.4 mmol of phosphate 4 times daily.

Oral
Hypophosphataemia
Adult: Up to 100 mmol of phosphate daily.
Contraindications
Severe renal impairment, hyperkalaemia, hypocalcaemia, infected phosphate renal calculi.
Special Precautions
Monitor serum electrolyte levels particularly Ca levels, ECG and renal function during the course of therapy esp if K phosphate is administered parenterally. Pregnancy; lactation. Elderly, debilitated patients and those with pre-existing electrolyte disturbances.
Adverse Reactions
Hyperphosphataemia esp in renal failure which may lead to hypocalcaemia and ectopic calcification esp in hypercalcaemic patients. Hypotension and organ damage due to tissue calcification which may cause acute renal failure. Hyperphosphataemia, hypocalcaemia, tissue calcification; nausea, vomiting, diarrhoea, abdominal pain, flatulence; bradycardia; hyperkalaemia; weakness; dyspnoea.
Potentially Fatal: Acute renal failure, arrhythmia, chest pain, decreased urine output, dyspnoea, oedema, mental confusion, paralysis, paresthesias, phlebitis, tetany (with large doses).
IV/Parenteral/PO: C
Drug Interactions
Reduced absorption when used with Aluminium, Ca or Mg salts due to binding with the phosphate ion of K phosphate. GI absorption is increased by vit D thus, increasing the risk of hyperphosphataemia. Concomitant admin with drugs increasing serum-potassium concentrations may increase the risk of hyperkalaemia. Increased effect of digitalis may also result to increased digitalis effect.
Lab Interference
Decreases serum ammonia concentration.
Action
Description: Potassium phosphate is involved in bone deposition, calcium metabolism regulation, acid-base equilibrium buffering and various enzyme systems. It is also vital in maintaining intracellular tonicity, nerve impulse transmission, cardiac contraction, skeletal and smooth muscle, normal renal function maintenance, carbohydrate utilisation, protein synthesis, nerve conduction regulation and muscle contraction esp cardiac muscles.
Pharmacokinetics:
Absorption: Following oral admin, approx 66% is absorbed.
Distribution: Enters the extracellular fluid then actively transported into cells.
Excretion: Via urine, 80-90% of K phosphate; remainder via faeces.
Storage
Store at room temperature.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Potassium phosphate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in